Interventions for preventing thrombosis in solid organ transplant recipients.

Area of Science:

• Transplantation Medicine
• Thrombosis Prevention
• Pharmacological Interventions

Background:

• Graft thrombosis is a major cause of solid organ transplant failure.
• Standardized thromboprophylaxis protocols are currently lacking.
• Heparins and antiplatelet agents are considered for prophylaxis, but carry bleeding risks.

Purpose of the Study:

• To assess the benefits and harms of thromboprophylaxis in solid organ transplant recipients.
• To evaluate the efficacy of anticoagulants and antiplatelets in preventing graft thrombosis.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) and quasi-RCTs.
• Searched multiple databases including Cochrane, MEDLINE, EMBASE, and clinical trial registries.
• Included all donor types and recipient age groups; assessed risk of bias and certainty of evidence using GRADE.

Main Results:

• Nine studies (712 participants) were included, primarily focusing on kidney and liver transplants.
• Evidence for heparin's efficacy in preventing graft thrombosis is very low certainty.
• Unfractionated heparin (UFH) may offer little or no difference in major bleeding events in kidney transplants, but may increase risk.
• Evidence for antiplatelet agents and interventions in liver transplants is unclear due to study limitations and lack of data.

Conclusions:

• A significant lack of high-quality research hinders conclusions on thromboprophylaxis efficacy in solid organ transplantation.
• It remains unclear if any therapy reduces early graft thrombosis; UFH may increase bleeding risk in kidney recipients.
• Further RCTs are needed to compare anticoagulants and antiplatelets against placebo, focusing on graft thrombosis, bleeding, and survival.